Imaging oxygenation of human tumours

European Radiology

Volumn 17, Issue 4, 2007, Pages 861-872

  Padhani, Anwar R ^a   Krohn, Kenneth A ^b   Lewis, Jason S ^c   Alber, Markus ^d  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

BOLD MRI; Cancer; Cu ATSM PET; F MISO PET; Hypoxia; Radiotherapy; Tumour Resistance

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE)COPPER; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE)COPPER CU 60; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE)COPPER CU 64; FLUORODEOXYGLUCOSE F 18; OXYGEN; TRACER; UNCLASSIFIED DRUG;

BLOOD OXYGENATION; BREAST ADENOCARCINOMA; CANCER RADIOTHERAPY; DRUG ACCUMULATION; DRUG HALF LIFE; DRUG RETENTION; GLIOMA; HUMAN; HYPOXIA; IMAGING SYSTEM; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SARCOMA; SOLID TUMOR; TUMOR;

CELL HYPOXIA; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY, CONFORMAL;

EID: 34248646775     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-006-0431-y     Document Type: Review

References (55)

1. Gray LH, Conger AD, Ebert M (1953) The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26:638-648
2. Vaupel P (2004) The role of hypoxia-induced factors in tumor progression. Oncologist 9:10-17
3. Brown JM (1999) The hypoxic cell: A target for selective cancer therapy-Eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 59:5863-5870
4. Vaupel P, Harrison L (2004) Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response. Oncologist 9:4-9
5. Vaupel P, Kelleher DK, Hockel M (2001) Oxygen status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28:29-35
6. Kallinowski F, Zander R, Hoeckel M, Vaupel P (1990) Tumor tissue oxygenation as evaluated by computerized-pO2-histography. Int J Radiat Oncol Biol Phys 19:953-961
7. Vaupel P, Schlenger K, Knoop C, Hockel M (1991) Oxygenation of human tumors: Evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 51:3316-3322
8. Brizel DM, Rosner GL, Harrelson J, Prosnitz LR, Dewhirst MW (1994) Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 30:635-642
9. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56:4509-4515
10. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, Terris DJ, Overgaard J (2005) Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77:18-24
11. Powis G, Kirkpatrick L (2004) Hypoxia inducible factor-1{alpha} as a cancer drug target. Mol Cancer Ther 3:647-654
12. Belozerov VE, Van Meir EG (2005) Hypoxia inducible factor-1: A novel target for cancer therapy. Anticancer Drugs 16:901-909
13. Hockel M, Vaupel P (2001) Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266-276
14. Caldwell JH, Revenaugh JR, Martin GV, Johnson PM, Rasey JS, Krohn KA (1995) Comparison of fluorine-18-fluorodeoxyglucose and tritiated fluoromisonidazole uptake during low-flow ischemia. J Nucl Med 36:1633-1638
15. Hall EJ, Giaccia AJ (2006) Oxygen effect and reoxygenation. In: Hall EJ, Giaccia AJ (eds) Radiobiology for the Radiologist. Lippincott Williams & Wilkins, Philadelphia, pp 85-105
16. Ciocca DR, Calderwood SK (2005) Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10:86-103
17. Bussink J, Kaanders JH, van der Kogel AJ (2003) Tumor hypoxia at the micro-regional level: Clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 67:3-15
18. Williams KJ, Parker CA, Stratford IJ (2005) Exogenous and endogenous markers of tumour oxygenation status: Definitive markers of tumour hypoxia? Adv Exp Med Biol 566:285-294
19. Rajendran JG, Krohn KA (2005) Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 43:169-187
20. Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, Grierson JR, Lindsley KL, Lewellen TK, Krohn KA et al (1995) Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography.Int J Radiat Oncol Biol Phys 33:391-398
21. Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, Chin LK, Hofstrand PD, Grierson JR, Eary JF, Krohn KA (2003) [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 30:695-704
22. Ng P, Rajendran JG, Schwartz DL, Patterson LM, Scharnhorst J, Krohn KA (2003) Can [F-18] fluoromisonidazole PET imaging predict treatment response in head and neck cancer? J Nucl Med 44:128P
23. Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, Spence AM, Muzi M, Farwell DG, Krohn KA (2004) Hypoxia and glucose metabolism in malignant tumors: Evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 10:2245-2252
24. Hicks RJ, Rischin D, Fisher R, Binns D, Scott AM, Peters LJ (2005) Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 32:1384-1391
25. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A (1997) Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 38:1155-1160
26. Dearling JLD, Lewis JS, Mullen GED, Rae MT, Zweit J, Blower PJ (1998) Design of hypoxia-targeting radiopharmaceuticals: Selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med 25:788-792
27. Dearling JLJ, Lewis JS, Welch MJ, McCarthy DW, Blower PJ (1998) Redox-active complexes for imaging hypoxic tissues: Structure-activity relationships in copper(II)bis(thiosemicarbazone) complexes. Chem Commun 22:2531-2533
28. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ (1999) The evaluation of 64 Cu-diacetyl-bis(N 4 -methylthiosemicarbazone)(64 Cu-ATSM) in vivo and in vitro in a hypoxic tumor model. J Nucl Med 40:177-183
29. Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ (2001) Tumor uptake of copper-diacetyl-bis(N 4 -methylthiosemicarbazone): Effect of changes in tissue oxygenation. J Nucl Med 42:655-661
30. Dearling JL, Lewis JS, Mullen GE, Welch MJ, Blower PJ (2002) Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem 7:249-259
31. Lewis JS, Herrero P, Sharp T, Engelbach JA, Fujibayashi Y, Laforest R, Kovacs A, Gropler RJ, Welch MJ (2002) Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis (N4-methylthiosemicarbazone). J Nucl Med 43:1557-1569
32. Maurer RI, Blower PJ, Dilworth JR, Reynolds CA, Zheng Y, Mullen GED (2002) Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem 45:1420-1431
33. Blower PJ, Lewis JS, Zweit J (1996) Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 23:957-980
34. Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, Welch MJ, A SB (2003) In vivo assesment of tumor hypoxia in lung cancer with 60 Cu-ATSM. Eur J Nucl Med Mol Imaging 30:844-850
35. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ (2003) Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60 Cu-ATSM: Relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 55:1233-1238
36. Howe FA, Robinson SP, McIntyre DJ, Stubbs M, Griffiths JR (2001) Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 14:497-506
37. Robinson SP, Rijken PF, Howe FA, McSheehy PM, Van Der Sanden BP, Heerschap A, Stubbs M, Van Der Kogel AJ, Griffiths JR (2003) Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry. J Magn Reson Imaging 17:445-454
38. Kostourou V, Robinson SP, Whitley GS, Griffiths JR (2003) Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging. Cancer Res 63:4960-4966
39. Carnell DM, Taylor NJ, Smith RE, Hoskin PJ, Stirling JJ, d'Arcy J, Walker-Samuel S, Collins DJ, Leach MO, Padhani AR (2005) Evaluation of prostate gland hypoxia with quantified BOLD MRI: Updated results from a correlated histological study. Miami, pp 270
40. Taylor NJ, Baddeley H, Goodchild KA, Powell ME, Thoumine M, Culver LA, Stirling JJ, Saunders MI, Hoskin PJ, Phillips H, Padhani AR, Griffiths JR (2001) BOLD MRI of human tumor oxygenation during carbogen breathing. J Magn Reson Imaging 14:156-163
41. Rijpkema M, Kaanders JH, Joosten FB, van der Kogel AJ, Heerschap A (2002) Effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and vascularity of head-and-neck tumors as measured by magnetic resonance imaging. Int J Radiat Oncol Biol Phys 53:1185-1191
42. Rodrigues LM, Howe FA, Griffiths JR, Robinson SP (2004) Tumor R2* is a prognostic indicator of acute radiotherapeutic response in rodent tumors. J Magn Reson Imaging 19:482-488
43. Neeman M (2002) Functional and molecular MR imaging of angiogenesis: Seeing the target, seeing it work. J Cell Biochem Suppl 39:11-17
44. Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, Koutcher JA (2000) Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 47:551-560
45. Brahme A (2003) Biologically optimized 3-dimensional in vivo predictive assay-based radiation therapy using positron emission tomography-computerized tomography imaging. Acta Oncol 42:123-136
46. Bentzen SM (2005) Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 6:112-117
47. Chao C, Bosch WR, Mutic S, Lewis JS, Dehdashti FD, Mintun MA, Demsey JF, Perez CA, Purdy JA, Welch MJ (2001) A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Biol Phys 49:1171-1182
48. Thorwarth D, Eschmann SM, Scheiderbauer J, Paulsen F, Alber M (2005) Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer 5:152
49. Ljungkvist AS, Bussink J, Rijken PF, Kaanders JH, van der Kogel AJ, Denekamp J (2002) Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 54:215-228
50. Collins DJ, Padhani AR (2004) Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges. IEEE Eng Med Biol Mag 23:65-83
51. Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, Krohn KA, Griffin TW (1992) Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 22:199-212
52. Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, Krohn KA (1996) Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 36:417-428
53. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, Machulla HJ, Bares R (2005) Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 46:253-260
54. Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, Wester HJ, Beck R, McEwan AJ, Wiebe LI, Schwaiger M (2005) Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 46:106-113
55. Evans SM, Kachur AV, Shiue CY, Hustinx R, Jenkins WT, Shive GG, Karp JS, Alavi A, Lord EM, Dolbier WR Jr, Koch CJ (2000) Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med 41:327-336